Figure 3
From: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
Analysis of cellular response following tivantinib treatment. (a) Effects of (-)-tivantinib (in μM), NaCl (20 mM) and the pan-GSK3 inhibitor LiCl (20 mM) on β-catenin and pGSK3α/β Y279/216 levels in HL60 cells. (b) Effects of tivantinib (in μM), NaCl (20 mM), and LiCl (20 mM) on PARP-1 and caspase 3 cleavage as well as pSer10 histone H3 levels after 4 and 24 h. (c) Cell cycle analysis by DAPI DNA staining following treatment of HL60 cells with DMSO, NaCl (20 mM), LiCl (20 mM), or tivantinib (1 μM) for 24 h. (d) Analysis of early and late apoptotic populations by Annexin V staining following treatment of HL60 cells for 4, 12, 18, or 24 h with DMSO, tivantinib (in μM), NaCl (20 mM), or LiCl (20 mM). (e) Cellular differentiation of HL60 cells following treatment with DMSO, tivantinib, NaCl or LiCl for 72 and 96 h as assessed by CD11b staining. Asterisk denotes p < 0.05 (*). Tiva = tivantinib.
